WHO工作组会议:制定肠道病毒71型疫苗质量、安全性与有效性推荐
2019年9月11–12日WHO在上海召开工作组会议,起草EV71疫苗质量、安全性与有效性推荐。会议回顾EV71流行病学及疫苗研发、监管与标准化,决定仅针对全病毒灭活疫苗制定推荐,不含VLP等研发阶段疫苗;大纲已定,拟2020年提交WHO ECBS审查采纳。
要点
- WHO推荐仅覆盖全病毒灭活EV71疫苗,不含VLP等其他类型。
- 会议回顾EV71流行病学及疫苗研发、生产、质控与标准化信息。
- 推荐草案拟经非正式磋商后于2020年提交WHO ECBS审查采纳。
核心结论
- 工作组同意制定WHO推荐,以保障全病毒灭活EV71疫苗的质量、安全性与有效性。
- 推荐范围仅限全病毒灭活疫苗,VLP等其他类型因仍在研发阶段不纳入。
研究设计与样本
- WHO于2019年9月11–12日在中国上海召开工作组会议,参会者包括起草组成员及来自疫苗研发方、生产商、监管机构和学术界的专家。
主要发现
- 会议回顾了EV71流行病学以及EV71疫苗的研发、监管和标准化情况。
- 疫苗研发方、生产商和监管机构介绍了EV71疫苗的研发、生产、质控和标准化信息。
- 工作组基于经验讨论了确定WHO对EV71疫苗质量、安全性与有效性立场的主要原则。
关键数值与推荐
- 推荐文件将遵循WHO推荐的通常格式,大纲已在会议上达成一致。
- 草案拟经WHO非正式磋商(含国家监管机构与疫苗生产商)讨论后,于2020年提交WHO ECBS审查和采纳。
局限性
- 推荐范围仅覆盖全病毒灭活EV71疫苗,不涵盖VLP等其他类型疫苗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Enterovirus A71 (EV71) is one of the major causative agents of hand, foot and mouth disease (HFMD), and is sometimes associated with severe central nervous system syndromes. Vaccines against EV71 infection have been developed or are in development in several countries and few have been licensed in China. In response to requests from some of these countries, WHO convened a working group meeting in Shanghai China from 11 to 12 September 2019 to develop WHO Recommendations to assure the quality, safety and efficacy of EV71 vaccines. Meeting participants included members of the drafting group, experts from vaccine developers, manufacturers, regulators and academia. The epidemiology of EV71, as well as the development, regulation and standardization of EV71 vaccines were reviewed in the meeting. Information on R&D, manufacturing, quality control and standardization of EV71 vaccines was presented by vaccine developers, manufacturers and regulators. Based on their experience, the working group discussed the main principles that would determine WHO's position on quality, safety and efficacy of EV71 vaccines. The working group agreed to develop WHO Recommendations to assure the quality, safety and efficacy of inactivated EV71 vaccines with a scope covering only whole virus inactivated vaccines. Other type of vaccines, such as EV71 virus-like particles (VLPs) will not be covered as they are still at the developmental stage. The outline of the document was agreed and will follow the usual style of WHO recommendations. It was also agreed to submit the draft Recommendations for review and adoption to the WHO ECBS in 2020 following discussion at a WHO informal consultation, which will include NRAs and vaccine manufacturers.
引用
- Lei D, Griffiths E, Martin J, et al. WHO working group meeting to develop WHO Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines. Vaccine. 2020. PMID: 32418797. doi:10.1016/j.vaccine.2020.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。